Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death.

Pandey N, Fahey MT, Jong YJ, O'Malley KL.

PLoS One. 2012;7(9):e45149. doi: 10.1371/journal.pone.0045149. Epub 2012 Sep 13.

2.

Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.

Belluzzi E, Greggio E, Piccoli G.

Biochem Soc Trans. 2012 Oct;40(5):1111-6. Review.

PMID:
22988874
3.

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.

Covy JP, Giasson BI.

Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Review.

4.

Possible involvement of the relationship of LRRK2 and autophagy in Parkinson's disease.

Bravo-San Pedro JM, Gómez-Sánchez R, Niso-Santano M, Pizarro-Estrella E, González-Polo RA, Fuentes JM.

Biochem Soc Trans. 2012 Oct;40(5):1129-33. Review.

PMID:
22988877
5.

Biochemical and pathological characterization of Lrrk2.

Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM.

Ann Neurol. 2006 Feb;59(2):315-22.

PMID:
16437584
6.

Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.

Vancraenenbroeck R, Lobbestael E, Weeks SD, Strelkov SV, Baekelandt V, Taymans JM, De Maeyer M.

Biochim Biophys Acta. 2012 Mar;1824(3):450-60. doi: 10.1016/j.bbapap.2011.12.009. Epub 2012 Jan 11.

PMID:
22251894
7.
8.

New biochemical approaches towards understanding the Parkinson's disease-associated kinase, LRRK2.

Liou GY, Gallo KA.

Biochem J. 2009 Oct 23;424(1):e1-3. doi: 10.1042/BJ20091540. Review.

PMID:
19839940
9.

Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.

Martin I, Kim JW, Lee BD, Kang HC, Xu JC, Jia H, Stankowski J, Kim MS, Zhong J, Kumar M, Andrabi SA, Xiong Y, Dickson DW, Wszolek ZK, Pandey A, Dawson TM, Dawson VL.

Cell. 2014 Apr 10;157(2):472-85. doi: 10.1016/j.cell.2014.01.064.

10.

LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.

Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.

Neuropathol Appl Neurobiol. 2011 Dec;37(7):777-90. doi: 10.1111/j.1365-2990.2011.01187.x.

PMID:
21696411
11.

GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Stafa K, Trancikova A, Webber PJ, Glauser L, West AB, Moore DJ.

PLoS Genet. 2012;8(2):e1002526. doi: 10.1371/journal.pgen.1002526. Epub 2012 Feb 9.

12.

Modeling Parkinson's disease using induced pluripotent stem cells.

Byers B, Lee HL, Reijo Pera R.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42. doi: 10.1007/s11910-012-0270-y. Review.

13.

Identification of the autophosphorylation sites of LRRK2.

Kamikawaji S, Ito G, Iwatsubo T.

Biochemistry. 2009 Nov 24;48(46):10963-75. doi: 10.1021/bi9011379.

PMID:
19824698
14.

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13.

15.

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. Epub 2005 Nov 3.

16.

I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule.

Ohta E, Katayama Y, Kawakami F, Yamamoto M, Tajima K, Maekawa T, Iida N, Hattori S, Obata F.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):710-5. doi: 10.1016/j.bbrc.2009.10.034. Epub 2009 Oct 13.

PMID:
19833102
17.

Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.

Yun H, Heo HY, Kim HH, DooKim N, Seol W.

Bioorg Med Chem Lett. 2011 May 15;21(10):2953-7. doi: 10.1016/j.bmcl.2011.03.061. Epub 2011 Mar 21.

PMID:
21474311
18.

Phosphorylation of LRRK2: from kinase to substrate.

Lobbestael E, Baekelandt V, Taymans JM.

Biochem Soc Trans. 2012 Oct;40(5):1102-10. Review.

PMID:
22988873
19.

LRRK2 and vesicle trafficking.

Sanna G, Del Giudice MG, Crosio C, Iaccarino C.

Biochem Soc Trans. 2012 Oct;40(5):1117-22. Review.

PMID:
22988875
20.

Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death.

Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, Melrose H, Farrer M, Wszolek ZK, Dickson DW, Tan EK.

Hum Mutat. 2011 Dec;32(12):1390-7. doi: 10.1002/humu.21582. Epub 2011 Sep 12.

PMID:
21850687
Items per page

Supplemental Content

Write to the Help Desk